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Background: Zimbabwe is a Southern African country with a high HIV-TB burden and is ranked 19
th among the
22 Tuberculosis high burden countries worldwide. Recurrent TB is an important problem for TB control, yet there is
limited information about treatment outcomes in relation to HIV status. This study was therefore conducted in
Chitungwiza, a high density dormitory town outside the capital city, to determine in adults registered with
recurrent TB how treatment outcomes were affected by type of recurrence and HIV status.
Methods: Data were abstracted from the Chitungwiza district TB register for all 225 adult TB patients who had
previously been on anti-TB treatment and who were registered as recurrent TB from January to December 2009.
The Chi-square and Fischer’s exact tests were used to establish associations between categorical variables.
Multivariate relative risks for associations between the various TB treatment outcomes and HIV status, type of
recurrent TB, sex and age were calculated using Poisson regression with robust error variance.
Results: Of 225 registered TB patients with recurrent TB, 159 (71%) were HIV tested, 135 (85%) were HIV-positive and 20
(15%) were known to be on antiretroviral treatment (ART). More females were HIV-tested (75/90, 83%) compared with
males (84/135, 62%). There were 103 (46%) with relapse TB, 32 (14%) with treatment after default, and 90 (40%) with
“retreatment other” TB. There was one failure patient. HIV-testing and HIV-positivity were similar between patients with
different types of TB. Overall, treatment success was 73% with transfer-outs at 14% being the most common adverse
outcome. TB treatment outcomes did not differ by HIV status. However those with relapse TB had better treatment
success compared to “retreatment other” TB patients, (adjusted RR 0.81; 95% CI 0.68 - 0.97, p = 0.02).
Conclusions: No differences in treatment outcomes by HIV status were established in patients with recurrent TB.
Important lessons from this study include increasing HIV testing uptake, a better understanding of what constitutes
“retreatment other” TB, improved follow-up of true outcomes in patients who transfer-out and better recording
practices related to HIV care and treatment especially for ART.
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Background
The global burden of tuberculosis (TB) is highest in the
Sub-Saharan Africa region [1] and this can be attributed
to the high prevalence of human immunodeficiency
virus infection (HIV) which is known to increase the
risk of developing TB [2,3]. Tuberculosis cases are
categorised as new and recurrent, the latter referring to
patients who have been previously treated. Recurrence
of TB can be attributed to relapse with a persistent
Mycobacterium tuberculosis strain [4] or reinfection
with a different strain [5,6]. Several studies have shown
that HIV infection increases the rate of TB recurrence
after successful completion of TB treatment in high
HIV endemic areas, with recurrence often being due to
a reinfection [6-9].
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ing that rates of recurrent TB can be reduced by
administration of rifampicin-based treatment [10],
there has been a steady increase in the number of
tuberculosis (TB) case notifications that are categorised
as recurrent or “retreatment”. Since 1995, when the
global DOTS framework was launched, up to 2008, the
annual number of retreatment cases globally has
increased from 59,240 to 775,403 [1]. In the WHO
Africa region, the annual number of notified retreat-
ment TB cases had increased from 15,133 in 1995 to
135,564 by the end of 2008, with 53,190 being relapse
cases and 82,374 being registered in other retreatment
categories [1]. In general, the treatment outcomes of
retreatment cases are not as good as with new cases of
TB as shown by global statistics for the 2008 cohorts,
whereby only 72% of retreatment cases (and 71% from
the Africa region) successfully completed treatment
[1].
Zimbabwe is a country in Southern Africa with a
population of 13 million and a large HIV-TB burden.
Zimbabwe, which ranks 19
th among the 22 Tuberculosis
high burden countries, had a TB incidence rate of 762
cases per 100,000 population and an HIV co-infection
prevalence of above 75% in 2008 [1]. There were 3631
(10%) notified retreatment cases out of a total of 36,650
cases registered in 2008, and these cases had a treat-
ment success rate that was reported at 73% compared
to 69% and 74% for new smear-positive TB cases and
new-smear negative/extra-pulmonary TB cases respec-
tively [1].
In 2008, the estimated number of retreatment TB
cases with multi-drug resistant (MDR) TB (resistant to
both isoniazid and rifampicin) was 8.3% (95% CI; 2.9-
22). However, from 2005 to 2009, there were no noti-
fied retreatment cases that were actually tested for
drug resistance [1], so this estimate cannot be con-
firmed. HIV-infected TB patients should now receive a
package of cotrimoxazole preventive therapy (CPT)
and antiretroviral therapy (ART), both of which can
reduce case fatality and increase treatment success if
administered early enough during anti-TB treatment
[11-15]. It is therefore important that TB patients
s h o u l du n d e r g oH I Vt e s t i n ga ss o o na sT Bi sd i a g -
nosed, so that they can access these adjunctive
therapies.
G i v e nt h eh i g hH I Vp r e v a l e n c ei nZ i m b a b w ea n dt h e
growing importance of recurrent TB, we determined in
o n ed i s t r i c ti nZ i m b a b w e( i )t h et y p eo ft u b e r c u l o s i si n
adult patients registered with recurrent TB, ii) the pro-
portion that were HIV tested with their results and (iii)
the treatment outcomes of recurrent TB patients in rela-
tion to type of TB and HIV status.
Methods
Study design
This was a retrospective record review of adult patients
registered as “recurrent TB”.
Study setting
All public health facilities in Chitungwiza were selected
for this study. Chitungwiza is a high density dormitory
town which is situated about 20 km from Zimbabwe’s
capital city, Harare, and has a population of 343 147
[16]. All health facilities consisting of a government cen-
tral hospital and four polyclinics, which are under the
Chitungwiza City Health Department, offer general
health services including TB treatment services. How-
ever, TB laboratory diagnosis through direct smear
microscopy examination is only carried out at the gov-
ernment central hospital where all collected sputum
smears in the district are sent. All health facilities offer
HIV counselling and testing services and cotrimoxazole
prophylaxis free of charge for confirmed HIV-positive
patients as recommended by the Zimbabwe National TB
Control Programme (NTP). In 2009 ART initiation and
HIV treatment and care services in Chitungwiza were
only offered at an ART initiating facility at the govern-
ment central hospital where all HIV-positive patients in
the district were referred.
TB Diagnosis and Definitions
Patients with recurrent TB will have been previously
treated for TB and are classified according to standard
WHO case definitions as either a relapse case (a patient
who completed treatment and presents again with
smear-positive PTB), treatment after failure (a patient
who failed first line treatment), treatment after default
(a patient who defaulted from treatment and presents
again with smear-positive PTB) or “retreatment other”
(all other recurrent TB cases) [2]. In the Zimbabwe
NTP, TB is diagnosed based on an initial clinical diag-
nosis and then a confirmative laboratory diagnosis
through direct smear microscopy of sputum smears
[17]. Those with smears positive for acid-fast bacilli are
diagnosed as smear-positive PTB, whilst those with
negative smears are referred for a chest radiograph. If
the latter is suggestive of TB, the patient is diagnosed as
smear-negative PTB. Extra-pulmonary TB (EPTB) is
mainly diagnosed on clinical grounds, along with cir-
cumstantial evidence and supporting specific diagnostic
tests [17].
After TB diagnosis, health workers at each health
facility complete notification forms and patient treat-
ment cards for all recurrent TB patients indicating diag-
nosis, patient category, treatment regimen and
monitoring indices. Patient information is then entered
into the DOTS register at each health facility, which is
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Chitungwiza. During the period of the study, HIV test-
ing was routinely offered to all TB patients, using the
parallel testing algorithm [18]. However as from 2010
the serial testing algorithm was adopted.
After diagnosis and registration, all recurrent TB
patients are given an 8-month standard re-treatment
regimen with first line drugs (2SHRZE/1HRZE/5HRE)
regardless of HIV status [17]. In Chitungwiza, treatment
was administered daily through health facility based
DOT during the first 2 months of the intensive phase.
Thereafter patients were given anti-TB drugs that ranged
from weekly to monthly supplies until completion of the
8-month treatment period. Patients have their sputum
specimens reviewed at 3 months, 5 months and at the
end of treatment as recommended in the national guide-
lines [17]. In Zimbabwe, cotrimoxazole preventive ther-
apy (CPT) is recommended for the whole duration of TB
treatment [19] whilst ART is recommended between 2
and 8 weeks after commencing TB treatment [20].
National TB treatment outcomes are in line with WHO
guidelines and are classified as treatment success (cured
plus treatment completed), defaulted, died, transferred
out or treatment failure. Cohort analyses of the registered
TB patients are done to declare their TB treatment out-
comes 12 months after the start of TB treatment.
Data collection
Data were collected for all adult TB patients registered
in the District TB register for Chitungwiza between 1
January 2009 and 31 December 2009 who had pre-
v i o u s l yb e e no nT Bt r e a t m e n tf o rm o r et h a no n e
month. An adult was defined as a person 18 years and
older. Patient data were abstracted from the District TB
registers between October 2010 and February 2011
using a data collection form, and variables that were col-
lected included:- TB registration number, age, sex, type
and category of recurrent TB, HIV status (HIV test
done or not done, HIV-negative or HIV-positive), treat-
ment outcome (treatment success, died, defaulter, trans-
ferred out and failure) and cotrimoxazole use. For
patients registered in 2009, ART data were not available
in the district TB registers, hence information about
ART use in HIV-infected TB patients was obtained
from the ART register at Chitungwiza Central hospital
ART clinic were HIV-infected patients were referred for
ART initiation in this district. TB registration numbers
were collected as patient identifiers but however patient
names had to be used to trace HIV-infected TB patients
commenced on ART from the ART register.
Statistical analysis
Patient information was coded, entered and cleaned
using Epidata version 3.1 statistical software. Data were
then imported and analysed using Stata 10 (Stata Cor-
poration, College Station, Texas). The Chi-squared test
or alternatively the Fischer’s Exact test was used to deter-
mine if there were associations between categorical vari-
ables. TB treatment outcomes were categorised into
binary data with possible outcome events being treat-
ment success, death, transfer-outs, defaulters and treat-
ment failure. Poisson regression with error variance was
then used to estimate multivariate-adjusted relative risks
for associations between the various TB treatment out-
comes and HIV status, type of recurrent TB, sex and age.
The modified Poisson regression model with the
robust error variance option was used as it is a better
approach for estimating relative risks for cohort studies
compared to using logistic regression [21]. Assumptions
of this statistical model were not violated as the model
provides relative biases and percentages of confidence
interval coverage which are reliable with a minimum
sample size of 100 [21]. Relative risks for treatment fail-
ure, however, could not be calculated as there were no
data in each subgroup to perform meaningful Poisson
regression analysis. The 5% significance level was used
in this study.
Ethics
Access to data in the TB registers was granted by the
Ministry of Health and Child Welfare whilst ethics
approval was obtained from the Medical Research
C o u n c i lo fZ i m b a b w ea n dt h eU n i o nE t h i c sA d v i s o r y
Group in Paris, France.
Results
Characteristics of patients with recurrent TB
There were 225 registered patients with recurrent TB, of
whom 135 (60%) were males. Results of HIV testing and
documented referral of HIV-infected TB patients to
ART are shown in Additional file 1: Figure S1. Just over
70% of patients were tested for HIV and of these
patients 85% were HIV-positive, but only 15% were
documented as being initiated on ART. There were no
data in the registers about initiation of HIV-infected TB
patients on CPT. Table 1 shows results of HIV testing
and HIV serostatus in relation to type of TB, sex and
age. Proportions of patients HIV tested were similar
across all the different types of recurrent TB (p =
0.476). However, HIV-positivity had a borderline asso-
ciation with type of TB (p = 0.052) being highest among
relapse cases (89%) compared to treatment after default
patients (70%) - p = 0.037. Though more females were
tested (75/90, 83%) compared to males (84/135, 62%) -
p = 0.001, HIV-positivity was similar between the 2
groups. HIV testing was highest in the 45 to 54 year age
group (87%) compared to other age groups but HIV-
positivity was similar (p > 0.99) across the age groups.
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status
Treatment outcomes for all patients with recurrent TB in
relation to HIV status, type of TB, sex and age group are
shown in Table 2. The treatment success rate was 73%
for all TB patients, regardless of HIV status. Patients who
transferred out (14%) constituted the majority of those
with adverse treatment outcomes, with 15 (49%) being
HIV-positive with undocumented ART status. For all
patients, treatment success rates were similar regardless
of HIV status (HIV test done or not done, HIV test posi-
tive or negative). Treatment success rates were also simi-
lar when stratified by sex and age group, with transfer
outs being the most common adverse outcomes. TB
treatment success rate was however highest in those with
relapse TB (80%) compared to “retreatment other” TB
patients (adjusted RR 0.81; 95% CI 0.68 - 0.97, p =0 . 0 2 ) .
For all other adverse treatment outcomes, there were no
significant multivariate-adjusted relative risks for associa-
tions with HIV status, type of TB, sex and age.
Table 1 HIV testing and HIV serostatus in relation to TB type, sex and age
Variable Number registered Number (%) HIV tested
ǂP-value Number (%) HIV-positive P-value
All patients 225 159 (71) - 135 (85) -
Type of TB*
Relapse 103 72 (70) 0.476 64 (89) 0.052
Treatment after default 32 20 (63) 14 (70)
Retreatment other 90 67 (74) 57 (85)
Sex
Female 90 75 (83) 0.001 66 (88) 0.357
Male 135 84 (62) 69 (82)
Age group
< 25 16 11 (69) 0.039 10 (91) > 0.99
25 - 44 147 99 (67) 83 (84)
45 - 54 39 34 (87) 29 (85)
≥ 55 23 15 (65) 13 (87)
TB tuberculosis, HIV human immunodeficiency syndrome
Table 2 TB treatment outcomes for all recurrent TB patients in relation to HIV status, type of TB, sex and age












All patients 225 163 (73) 13 (6) 14 (6) 32 (14) 1 (< 1)
HIV status
a
HIV-negative 21 15 (71) 2 (10) 2 (10) 2 (10) 0 (0)
HIV-not done 64 44 (69) 2 (3) 5 ( 8) 13 (20) 0 (0)
HIV-positive (ART not documented) 115 87 (76) 6 (5) 5 ( 4) 15 (13) 1 (1)
HIV-positive (on ART) 20 14 (70) 2 (10) 2 (10) 1 ( 5) 0 (0)
Type of TB
Relapse TB 103 82 (80) 4 (4) 6 (6) 11 (11) 0 (0)
Treatment after default 32 21 (68) 2 (6) 3 (10) 5 (16) 0 (0)
Retreatment other 90 60 (67)* 7 (8) 5 (6) 16 (18) 1 (1)
Sex
Female 90 68 (76) 5 (6) 6 (7) 10 (11) 0 (0)
Male 135 95 (71) 8 (6) 8 (6) 22 (16) 1 (1)
Age group (in years)
< 25 16 12 (80) 1 (7) 0 (0) 2 (13) 0 (0)
25 - 44 147 108 (74) 6 (4) 11 (8) 21 (14) 0 (0)
45 - 54 39 26 (67) 5 (13) 2 (5) 5 (13) 1 (3)
≥ 55 23 17 (74) 1 (4) 1 (4) 4 (17) 0 (0)
a 2 patients with unrecorded HIV status and 3 with HIV-indeterminate results have been excluded;
b 2 patients with unrecorded TB treatment outcomes have
been excluded
TB tuberculosis, ART antiretroviral treatment, HIV human immunodeficiency virus
Significant statistical comparisons using multivariate Poisson regression: * p < 0.05 compared with relapse TB
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This study in Chitungwiza district in Zimbabwe
showed a very high HIV prevalence in patients regis-
tered with recurrent TB, but we did not find signifi-
cant differences in treatment outcomes in relation to
HIV status, age or sex. However, relapse TB patients
had better treatment success compared to “retreatment
other” TB patients.
T h e r ea r ean u m b e ro fi m p o r t a n tf i n d i n g sf r o mo u r
study. Although HIV testing should be offered to all
registered patients with TB, nearly one third of those
w i t hr e c u r r e n tT Bh a dn oH I Vt e s td o n e .W ed on o t
know the reasons for this, and this particular issue
deserves further investigation. HIV testing uptake was
much better in females than males, and better strategies
of encouraging males to be HIV tested need to be found
and assessed.
The majority of patients with recurrent TB were HIV-
positive, yet only 15% were documented to be receiving
ART. There may be several reasons for this that include
poor referral and access to ART services by HIV-TB
patients in Chitungwiza district or a poor recording and
reporting system. For patients registered in 2009, the
only way to find whether HIV-TB patients had accessed
ART was to review the ART registers for Chitungwiza
district and try to match the names of HIV-infected TB
patients with those from the TB register - matching was
not possible and this is therefore a limitation of the
study. HIV-TB patients who had transferred out and
started ART in another district would also not be identi-
fied by this method and therefore missed for the pur-
poses of this study. Since 2010, HIV and TB activities
have been integrated into TB registers, and there should
now be better data on ART. There was also no record
of CPT use in the TB register and this needs improve-
ment as well.
Finally, there was a high transfer out rate which
adversely impacted on treatment success. A transfer out
is defined as a patient who has been transferred to a
health facility in another district and the treatment out-
come results have not been reported back to the refer-
ring treatment unit who have the duty to report on
these patients. This is an area where the Zimbabwe
NTP needs to improve and ensure that centres who
receive transfer-in patients report back the treatment
outcomes to the facilities that initiated TB treatment.
This was a district based study where data were col-
lected for TB patients under routine programme condi-
tions. Hence, it may be difficult to ensure completeness,
consistency and accuracy of data. Our study sample was
small therefore it may have reduced the power of the
study. We also were unable to adjust for the potential
confounding effect of ART and TB treatment
c o m p l i a n c ea n dd i s e a s es e v e r i t yw h e na s s e s s i n gt h e
association between TB treatment outcomes and HIV
status as the data were unavailable.
Conclusions
In conclusion, there are some important lessons to learn
from the study. More attention should be paid to dis-
secting out the various categories of patients who are
classified together under “retreatment other” to deter-
mine whether outcomes are similar or different. Relapse
patients appear to do better, but the power of our sam-
ple may have been insufficient to detect this. Improving
the follow up of outcomes in transferred out patients
coupled with better recording practices of HIV care and
treatment will allow better analysis of the relationship
between TB treatment outcomes and HIV status. Trans-
fer outs may also be lessened by integration of TB treat-
ment services and ART initiation in all health facilities.
There needs to be a higher uptake of HIV testing in
TB patients, especially in males. If those found HIV-
positive are followed up and given CPT and early ART,
this may improve overall treatment outcomes. There
needs to be much better recording practices of HIV
care and treatment, especially with regard to CPT and
ART. Future research of a prospective nature with a lar-
ger cohort of recurrent TB patients may more clearly
establish the impact of HIV testing on TB treatment
outcomes under programmatic conditions.
Additional material
Additional file 1: Figure S1. HIV testing status and known referral to
antiretroviral treatment for recurrent tuberculosis patients in Chitungwiza
district, Zimbabwe (Jan - Dec 2009).
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